Arboretum’s advisory board includes world-renowned leaders in healthcare with extensive experience developing companies and improving patient care. The board’s expertise extends beyond the private sector to healthcare policy and ongoing payment reform initiatives. The advisors provide strategic advice and a valuable network of contacts to Arboretum and its portfolio companies.

Ronald DollensRonald W. Dollens
Ronald W. Dollens is the retired president and CEO of Guidant Corporation, a Fortune 500 company acquired in 2006 for $27 billion by Boston Scientific. Mr. Dollens assumed the post as president and CEO of Guidant in 1994 when the company was formed as a result of a spin-out of Eli Lilly and Company, where he was the president of the Medical Devices and Diagnostic division. Mr. Dollens is currently Lead Director of Halyard Health Inc., formerly Kimberly-Clark Health Care, the past non-executive Chairman of the Board, Kinetic Concepts Inc., previously a Director for Abiomed Inc. and Beckman Coulter Corp. . Mr. Dollens received a BS in Pharmacy and Pharmacal Sciences from Purdue University and an MBA from Indiana University.

William HawkinsWilliam A. Hawkins
Mr. Hawkins is the Former Chairman and CEO of Medtronic and is currently advising Private Equity and Venture Capital groups as well as serving on multiple for profit and non for-profit boards. Mr. Hawkins was President and CEO of Immucor from Oct 2011 to July 2015. Prior to Immucor Mr. Hawkins served as Chairman and CEO of Medtronic. Mr. Hawkins assumed the role of CEO in 2007 and became Chairman of the Board in 2008. He joined Medtronic in 2002 as SVP and President of Medtronic Vascular. Prior to Medtronic, Mr. Hawkins served as President and Chief Executive Officer of Novoste Corp. Nasdaq (NOVT). He was recently elected to the National Academy of Engineering and is an AIMBE Fellow. Mr. Hawkins is Lead Director at Immucor and is Vice Chair of the Board of the Duke University Health System. Mr. Hawkins received his bachelor's degree in electrical and biomedical engineering from Duke University and an MBA from the University of Virginia.

Raymond Huggenberger Raymond Huggenberger
Raymond Huggenberger has served as a Member of the Board of Directors of Inogen (Nasdaq: INGN) since 2008. Previously, Mr. Huggenberger served as the company's Chief Executive Officer from January 2008 to February 2017. Prior to joining Inogen, Mr. Huggenberger held various management positions with Sunrise Medical Inc., a global manufacturer and distributor of durable medical equipment, including President and COO. Mr. Huggenberger also held a consultant position with McDermott and Bull Inc., an executive search firm and the position of Managing Director in the healthcare division of TA Triumph Adler AG, a document process management firm. Mr. Huggenberger currently serves on the Board of Directors of Inogen and Wellfount Corporation and previously served on the Board of Directors of IYIA Technologies. Mr. Huggenberger graduated from AKAD University in Rendsburg, Germany in Economics and completed the Advanced Marketing Strategies Program at INSEAD, Fontainebleau, France.

Stephane MouradianStephane Mouradian
Stephane Mouradian is director of business development at Illumina. He oversees Illumina’s companion diagnostic partnerships in oncology with pharmaceutical companies. Previously, Stephane led Illumina’s expansion of NIPT (Non Invasive Prenatal Testing) in Europe and Illumina’s venture investments in start-ups Twist and Boreal Genomics, for which he serves as Illumina-appointed board observer. Prior to Illumina, he was at Caliper Lifesciences for 15 years. He developed and launched several microfluidic DNA testing products that became standards in genomic laboratories today, and he led corporate development for Caliper. Stephane holds a Ph.D. in Analytical Chemistry from the University of Wisconsin, Madison and a Master’s degree in Chemical Engineering from Strasbourg University, France.

Roger NewtonRoger Newton, PhD
Roger Newton is currently Founder, Scientific Advisor and Board Member of Esperion, and also a Fellow of the American Heart Association and American College of Nutrition. After spinning Esperion out of Pfizer in 2008, Roger was President and CEO and later its Executive Chairman and CSO. Previously, Roger was Co-founder, President & CEO of the original Esperion from July 1998 until its acquisition by Pfizer for $1.3 Billion in 2004. Prior to founding the original Esperion, Roger was Chairman of the Atherosclerosis Drug Discovery Team at Warner Lambert from 1981 to 1998 during which he was a co-discoverer and product champion of Lipitor®, the largest selling pharmaceutical in the world. Roger is a director of several life science companies, including Celsee Diagnostics, FirstSense Medical and Juventas Therapeutics. Roger earned a PhD in Nutrition from the University of California, Davis, an MS in Nutritional Biochemistry from the University of Connecticut, and a BS in Biology from Lafayette College.

Mike RhodinMike Rhodin
Mike Rhodin recently retired from IBM after 33 years, and 7 years as a corporate officer. Most recently he was responsible for founding the IBM Watson business units. Prior to that, Mike founded IBM’s solution units around their Smarter Planet initiatives including Smarter Cities, Smarter Commerce and Smarter Analytics. Mr. Rhodin began his professional career in 1984 where he joined IBM as software engineer. He held various technology and management roles until 1997 when he moved to corporate headquarters and started his executive management career. He is a member Supervisory Board for TomTom, a member of the International Advisory Board for Santander and a member of the National Advisory Board for the University of Michigan Computer Science program. Mike received a Bachelor of Science (Computer Science) degree from University of Michigan and was recognized with an Alumni Merit Award in 2016. He was also recognized with an honorary Doctor of Science degree from Roanoke College for his contributions to the development of artificial intelligence systems.

Nancy SchlichtingNancy Schlichting
Nancy Schlichting is retired Chief Executive Officer of Henry Ford Health System (HFHS), a nationally recognized $5.5 billion health care organization with 27,000 employees and recipient of the 2011 Malcolm Baldrige National Quality Award. She is credited with leading the health system through a dramatic financial turnaround and for award-winning patient safety, customer service and diversity initiatives.. Nancy joined HFHS in 1998 as its Senior Vice President and Chief Administrative Officer and was named President and CEO in 2003. Retiring in 2017, her career in health care administration spans over 35 years of experience in senior level executive positions. Nancy received her AB in Public Policy Studies, Magna Cum Laude from Duke University and her MBA from Cornell University.

Mariana Udow-PhillipsMarianne Udow-Phillips
Marianne Udow-Phillips is the Executive Director of the Center for Healthcare Research & Transformation (CHRT) at the University of Michigan. CHRT is an independent 501(c)(3) impact organization with a mission to advance evidence-based care delivery, improve population health, and expand access to care. From 2004 through 2007, Marianne was director of the Michigan Department of Human Services, appointed by Governor Jennifer M. Granholm. Marianne came to state service from Blue Cross Blue Shield of Michigan, where she served in leadership roles for over 20 years, most recently as senior vice president of Health Care Products and Provider Services. She holds a master’s degree in Health Services Administration from the U-M School of Public Health.

Jeff WilliamsJeffery S. Williams
Jeff Williams is CEO and Chairman of the Board at NeuMoDx Molecular. Prior to that, he joined Accuri Cytometers, a venture-funded life sciences company, as its President and CEO in January 2010, leading to a sale of the company to BD in March 2011. Prior to Accuri, Mr. Williams became President and CEO of HandyLab, Inc., a clinical diagnostic company, in 2004. HandyLab was acquired by BD in November 2009 for $275 million. Previously, Mr. Williams was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997, culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in 2002. He received a BS in Biology from Alma College and an MBA from The University of Michigan.

Loading posts...